Header Logo

Connection

Alan Landay to RNA, Viral

Back to Details
This is a "connection" page, showing publications Alan Landay has written about RNA, Viral.
Alan Landay
Connection Strength
2.772
RNA, Viral
  1. HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS. 2014 Mar 13; 28(5):739-43.
    View in: PubMed
    Score: 0.472
  2. Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses. 2008 Jul; 24(7):973-6.
    View in: PubMed
    Score: 0.318
  3. Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunol Med Microbiol. 2005 Aug 01; 45(2):129-36.
    View in: PubMed
    Score: 0.254
  4. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15; 210(8):1248-59.
    View in: PubMed
    Score: 0.119
  5. A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment. J Interferon Cytokine Res. 2011 Jun; 31(6):481-3.
    View in: PubMed
    Score: 0.095
  6. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009 Oct 15; 200(8):1212-5.
    View in: PubMed
    Score: 0.087
  7. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008 May 15; 197(10):1402-7.
    View in: PubMed
    Score: 0.079
  8. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007 Mar 01; 44(5):749-54.
    View in: PubMed
    Score: 0.072
  9. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20.
    View in: PubMed
    Score: 0.060
  10. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003 Dec 15; 188(12):1804-14.
    View in: PubMed
    Score: 0.058
  11. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2003 Nov 15; 188(10):1444-54.
    View in: PubMed
    Score: 0.058
  12. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003 Jul 15; 188(2):209-18.
    View in: PubMed
    Score: 0.056
  13. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003 Mar 07; 17(4):455-80.
    View in: PubMed
    Score: 0.055
  14. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS. 2001 Sep 07; 15(13):1635-41.
    View in: PubMed
    Score: 0.050
  15. Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nat Commun. 2021 06 29; 12(1):3922.
    View in: PubMed
    Score: 0.049
  16. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000 May 05; 14(7):761-70.
    View in: PubMed
    Score: 0.045
  17. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000 Jan; 181(1):358-63.
    View in: PubMed
    Score: 0.044
  18. Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 01; 19(4):408-12.
    View in: PubMed
    Score: 0.041
  19. High prevalence of hepatitis G virus RNA and antibody to probable viral envelope protein but not both in AIDS patients' plasma. AIDS. 1998 Mar 26; 12(5):530-1.
    View in: PubMed
    Score: 0.039
  20. Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. J Infect Dis. 2017 10 17; 216(7):813-818.
    View in: PubMed
    Score: 0.038
  21. Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):155-62.
    View in: PubMed
    Score: 0.034
  22. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. J Immunol. 1996 Jan 15; 156(2):841-51.
    View in: PubMed
    Score: 0.034
  23. A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Aug 01; 66(4):399-406.
    View in: PubMed
    Score: 0.030
  24. Hepatitis C viremia is associated with cytomegalovirus IgG antibody levels in HIV-infected women. PLoS One. 2013; 8(4):e61973.
    View in: PubMed
    Score: 0.028
  25. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013 Jun 06; 121(23):4635-46.
    View in: PubMed
    Score: 0.028
  26. Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis. 2012 Sep 01; 206(5):780-9.
    View in: PubMed
    Score: 0.026
  27. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
    View in: PubMed
    Score: 0.026
  28. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011 Jan 14; 25(2):159-64.
    View in: PubMed
    Score: 0.024
  29. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010 Jul 17; 24(11):1657-65.
    View in: PubMed
    Score: 0.023
  30. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010 Mar 15; 201(6):823-34.
    View in: PubMed
    Score: 0.022
  31. Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol. 2009 Apr; 16(4):499-505.
    View in: PubMed
    Score: 0.021
  32. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
    View in: PubMed
    Score: 0.021
  33. In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits. Clin Vaccine Immunol. 2008 Sep; 15(9):1398-409.
    View in: PubMed
    Score: 0.020
  34. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008 Jun 19; 22(10):1131-5.
    View in: PubMed
    Score: 0.020
  35. Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses. 2008 Feb; 24(2):163-8.
    View in: PubMed
    Score: 0.019
  36. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med. 2007 Mar 26; 167(6):597-605.
    View in: PubMed
    Score: 0.018
  37. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
    View in: PubMed
    Score: 0.018
  38. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19; 366(9485):549-55.
    View in: PubMed
    Score: 0.016
  39. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis. 2004 Dec 01; 190(11):1970-8.
    View in: PubMed
    Score: 0.015
  40. HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis. 2004 Aug 01; 190(3):619-23.
    View in: PubMed
    Score: 0.015
  41. Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 2004 Mar 05; 18(4):605-13.
    View in: PubMed
    Score: 0.015
  42. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
    View in: PubMed
    Score: 0.015
  43. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01; 34(3):295-8.
    View in: PubMed
    Score: 0.014
  44. Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003 Aug 01; 33(4):448-60.
    View in: PubMed
    Score: 0.014
  45. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis. 2003 Feb 01; 187(3):375-84.
    View in: PubMed
    Score: 0.014
  46. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001 Nov 10; 358(9293):1593-601.
    View in: PubMed
    Score: 0.013
  47. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.
    View in: PubMed
    Score: 0.012
  48. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000 Dec 01; 25(4):289-95.
    View in: PubMed
    Score: 0.012
  49. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000 Dec 01; 14(17):2635-42.
    View in: PubMed
    Score: 0.012
  50. Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000 Oct 01; 25(2):150-6.
    View in: PubMed
    Score: 0.012
  51. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS. 2000 Sep 29; 14(14):2101-7.
    View in: PubMed
    Score: 0.012
  52. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb; 181(2):491-7.
    View in: PubMed
    Score: 0.011
  53. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.
    View in: PubMed
    Score: 0.011
  54. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000 Jan; 181(1):148-57.
    View in: PubMed
    Score: 0.011
  55. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS. 1999 Jul 30; 13(11):1295-303.
    View in: PubMed
    Score: 0.011
  56. HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. AIDS. 1999 Jul 09; 13(10):1177-85.
    View in: PubMed
    Score: 0.011
  57. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr; 179(4):799-807.
    View in: PubMed
    Score: 0.010
  58. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.
    View in: PubMed
    Score: 0.010
  59. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997 Jul; 11(8):1013-21.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.